December 10, 2010
SymBio Pharmaceuticals Limited

SymBio Launches TREAKISYM® in JapanTOKYO, Japan, December 10, 2010 -- SymBio Pharmaceuticals Limited (Headquarters: Tokyo,President & CEO: Fuminori Yoshida, “SymBio”) announced today the launch of TREAKISYM®
(SyB L-0501, bendamustine hydrochloride) in Japan for the treatment of refractory/relapsed
low-grade B-cell non-Hodgkin’s lymphoma and mantle cell lymphoma. This marks theachievement of a major corporate milestone in SymBio’s history, transforming the company into abiopharmaceutical company with solid product revenue in 2011.
In August, 2008, SymBio concluded a license agreement with Eisai Co., Ltd. (Headquarters: Tokyo,President & CEO: Haruo Naito, “Eisai”) for the co-development and commercializationof TREAKISYM in Japan. In accordance with the agreement, Eisai has assembled a team ofdedicated oncology-focused liaisons to oversee each major market area in Japan along with 1,400
medical reps to promote and detail TREAKISYM®.
TREAKISYM® is the first oncology drug in-licensed by SymBio (December, 2005) for developmentand commercialization in Japan and other key Asia Pacific markets. The Ministry of Health,Labour and Welfare (MHLW) approved the company’s New Drug Application for TREAKISYM®
on October 27th this year. Flawless execution and nimbleness has enabled SymBio to shorten timeto market for TREAKISYM®, only requiring 4 years from first patient enrolled to market approval.
This short development timeline to market approval has enabled SymBio to markedly reduce thedrug lag between the US launch of TREANDA® and Japan launch of TREAKISYM® to two years,
and to almost zero drug lag between the European and Japan launches.
Fuminori Yoshida, President and CEO of SymBio, said, “I am extremely pleased that as a resultof the dedication and commitment invested by our people at SymBio, we have succeededin significantly shortening the drug lag between the launch of bendamustine in Japan and othercountries to deliver this much-needed cancer drug to patients as early as possible. The availabilityof this drug in Japan will greatly help non-Hodgkin's lymphoma and mantle cell lymphoma
patients who have suffered needlessly due to the lack of effective treatment. This
major achievement embodies the culmination of our efforts since the company’s inception in 2005
with the corporate mission of addressing the unmet medical needs of patients.”
As part of ongoing label expansion plans and through its collaboration with Eisai for future
development, SymBio initiated two additional phase 2 studies in 2010 for TREAKISYM®;
enrollment is currently underway for a Japan-Korea joint phase 2 trial of bendamustine in
combination with rituximab for the treatment of refractory and relapsed aggressive NHL, and as
first-line treatment in a phase 2 trial in untreated multiple myeloma patients.

SymBio will continue to expand the use of TREAKISYM® in the hematology space as nimbly as
possible in order to address the unmet medical needs of patients as its business presence in Asia
Pacific continues to gain momentum, and key pieces of the company’s strategic development andcommercialization plan fall into place upon the completion of important milestones.
Note to Editors

1.

About Bendamustine Hydrochloride
Bendamustine was first synthesized in the early 1960s in the former ‘East Germany’ byJenapharm, and is currently marketed in Germany under the brand name “Ribomustin®” as atreatment for non-Hodgkin’s lymphoma, multiple myeloma and chronic lymphocytic leukemia.
Mundipharma received marketing authorizations in several EU countries this year for thedrug under the brand name “Levact®.” In the United States, the drug has been approved by
the U.S. Food and Drug Administration and is marketed as TREANDA® for the treatment ofchronic lymphocytic leukemia and relapsed indolent B-cell non-Hodgkin's lymphoma.
SymBio Pharmaceuticals Limited originally acquired the exclusive right from Astellas
Deutschland GmbH (Headquarters: Munich, Germany, formerlly Astellas Pharma GmbH) todevelop and commercialize bendamustine hydrochloride in Japan (December, 2005), followedby signature of a second license agreement for the exclusive right to China/HK, South Korea,
Taiwan and Singapore (March, 2007).

2. About TREAKISYM®
Product Name:
TREAKISYM® for Injection, for intravenous infusion 100 mg
Generic Name:
Bendamustine hydrochloride
Indications and Usage:
For the treatment of relapsed or refractory forms of the following indications:・ Low-grade B-cell non-Hodgkin’s lymphoma
・ Mantle cell lymphoma
Dosage and Administration:
・ The standard adult dose of bendamustine hydrochloride is 120 mg/m2
infused intravenously over 60 minutes on Days 1 and 2 of repeated 21-daycycles. The dose may be reduced as deemed appropriate according to thepatient’s condition.
NHI Drug Price Standard: TREAKISYM® 100 mg 92,356 yen / vial
3. About SymBio Pharmaceuticals Limited
SymBio Pharmaceuticals Ltd. was established in March, 2005 by Fuminori Yoshida, whopreviously served concurrently as Corporate VP of Amgen Ltd. and founding President ofAmgen Japan (currently Takeda Bio Development Center Limited). The company’s
underlying corporate mission is “delivering hope to patients in need” as it aspires to be aleading specialty pharmaceutical company in Asia Pacific dedicated to addressing
underserved medical needs in the areas of oncology, hematology and autoimmune disease.

[Contact]
SymBio Pharmaceuticals Limited.
Investor Relations, Finance & Accounting Department
Tel: +081(0)3 5472 1123
URL: http://www.symbiopharma.com